~~<i id='E1282E5D60'><strike id='E1282E5D60'><tt id='E1282E5D60'><pre id='E1282E5D60'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

leisure time

Wikipedia

author：knowledge 2025-09-28 23:30:28 - browse：1

The Roche booth at ESMO in Madrid. — Roche's booth at the 2023 ESMO conference. Andrew Joseph/STAT

MADRID — A Roche drug lowered the risk of recurrence or death by 76% versus chemotherapy for patients with a type of early non-small cell lung cancer, according to data from a Phase 3 trial presented Saturday.

The findings, which Roche is planning to submit to regulators, could give patients with early-stage ALK-positive cancers another option. The standard treatment after surgery for these patients is chemotherapy.

The results from the Alina trial were presented here at the annual meeting of the European Society for Medical Oncology.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hollywood unions extend contract negotiations for actors
Next article： David Sabatini, ex

hotspot

focus

explore

focus

hotspot

entertainment

MaxineBernstein/TheOregonianviaAPWordspreadthroughanOregonhospitallastmonththatavisitorwascausingtro

WSS

Thousands in Haiti march to demand safety from violent gangs as killings and kidnappings soar

Trump lawyer welcomes Pence testifying in Jan. 6 trial, won't say if Trump will too

Childbirth

Gene therapies for deafness raise the question: Do deaf people want a 'cure'?

More people are opting for early dinners since the pandemic, says OpenTable CEO Debby Soo

In medicine, common shorthands can shortchange care

leisure time

Wikipedia

hotspot

Anesthesiologist group: stop taking Ozempic before surgery

Report: NIH

ChatGPT in medicine: STAT answers readers' burning questions

In medicine, common shorthands can shortchange care

Psychedelics group wrestles with new pharma identity

Prince Harry and Meghan to work on film adaptation of 'Meet Me at the Lake' novel

Apple is now the first public company to be valued at $3 trillion

Childbirth

In age of alternative facts, a scholarly course on calling out crap

First Opinion Podcast: What happens when kids become caregivers?

focus

Antibiotic resistance nearly killed me, so I'm raising awareness of it

Latest bird flu infection made farmworker sicker than earlier cases

Gene therapies for deafness raise the question: Do deaf people want a 'cure'?

Gene therapies for deafness raise the question: Do deaf people want a 'cure'?

Insmed lung disease drug hits target in key Phase 3 trial

Israel demolishes home of alleged Palestinian attacker, fueling West Bank tensions

explore

focus

hotspot

entertainment